PDF factsheet
      Z

weight-loss drugs in cardiovascular prevention for overweight or obese patients, clinical trials results

rimonabant versus placebo
STRADIVARIUS, 2008
NCT00124332
rimonabant 20 mg daily
versus
placebo
patients with abdominal obesity and the metabolic syndromedouble-blind
North America, Europe, and Australia
CRESCENDO, 2010
NCT00263042
rimonabant 20 mg
versus
placebo
patients patients with abdominal obesity and with previously manifest or increased risk of vascular diseasedouble-blind
Follow-up duration: 13.8 months
42 countries
rimonabant 20mg versus placebo
RIO europe 20mg, 2005
rimonabant 20mg daily
versus
placebo
patients with body-mass index 30 kg/m2 or greater, or body-mass index greater than 27 kg/m2 with treated or untreated dyslipidaemia, hypertension, or bothtž-dtDouble blind
Europe and USA
Rio-lipid 20 mg, 2005
rimonabant 20 mg daily
versus
placebo
overweight or obese patients (body-mass index 27 to 40) with untreated dyslipidemia (triglyceride levels >1.69 to 7.90 mmol per liter, or a ratio of cholesterol to high-density lipoprotein [HDL] cholesterol of >4.5 among women and >5 among men)Double blind
Follow-up duration: 12 months
worlwide (8 countries)
RIO-North America 20 mg, 2006
NCT00029861
rimonabant 20mg daily
versus
placebo
obese (body mass index >=30) or overweight (body mass index >=27 and treated or untreated hypertension or dyslipidemia) adult patientsDouble blind
US and Canada
rimonabant 20mg versus rimonabant 5mg
RIO europe (20 vs 5 mg), 2005

versus
rimonabant 5mg versus placebo
RIO europe 5mg, 2005
5 mg rimonabant
versus
placebo
patients with body-mass index 30 kg/m2 or greater, or body-mass index greater than 27 kg/m2 with treated or untreated dyslipidaemia, hypertension, or bothdouble-blind
Follow-up duration: 1 y

  Options


in first

in second

  Filter